- Home
- BWIN vs SLNO Comparison
BWIN vs SLNO Comparison
Compare BWIN & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$33.49
Company Overview
Basic Information| Metric | BWIN | SLNO |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | United States | United States |
| Employees | 4116 | N/A |
| Industry | Specialty Insurers | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.3B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | BWIN | SLNO |
|---|---|---|
| Price | $21.32 | $33.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | $32.33 | ★ $108.00 |
| AVG Volume (30 Days) | ★ 1.6M | 1.4M |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 108.90 |
| EPS | N/A | ★ 0.39 |
| Revenue | N/A | ★ $1,450,788.00 |
| Revenue This Year | $35.89 | $155.44 |
| Revenue Next Year | $11.44 | $57.99 |
| P/E Ratio | ★ N/A | $87.46 |
| Revenue Growth | N/A | ★ 138.82 |
| 52 Week Low | $15.88 | $32.63 |
| 52 Week High | $47.15 | $89.12 |
Technical Indicators
Market Signals| Indicator | BWIN | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 54.86 | 32.35 |
| Support Level | $19.30 | $32.63 |
| Resistance Level | $24.10 | $41.48 |
| Average True Range (ATR) | 1.22 | 2.36 |
| MACD | 0.24 | -0.47 |
| Stochastic Oscillator | 67.02 | 9.86 |
Price Performance
Historical Comparison BWIN
SLNO
About BWIN The Baldwin Insurance Group Inc.
The Baldwin Insurance Group Inc is a United States-based insurance distribution firm. Its products include Business Insurance, Benefits Consulting, Reinsurance, Specialty MGA, Embedded Insurance., Personal insurance, etc.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.